Clinical Trial

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-08.
Trial Details
NCT Number NCT07532902
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Bristol-Myers Squibb
Conditions Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
Enrollment 60 participants
Start Date 2026-04-07
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-29